Targeting the Androgen Signaling Axis in Prostate Cancer
Journal of Clinical Oncology · 10.09.2023 · 41 (26) · 4267-4278
DOI: 10.1200/jco.23.00433 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2023. Verfasst von Charles Dai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center, Boston, MA. Hauptthemen laut MEDLINE: Androgens, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to the pathophysiology of prostate cancer. Despite successful translational efforts in targeting AR, therapeutic resistance often occurs as a result of molecular alterations in the androgen signaling axis. The efficacy of next-generation AR-directed therapies for castration-resistant prostate cancer has provided crucial clinical validation for the continued dependence on AR signaling and introduced a range of new treatment options for men with both castration-resistant and castration-sensitive disease. Despite this, however, metastatic prostate cancer largely remains an incurable disease, highlighting the need to better understand the diverse mechanisms by which tumors thwart AR-directed therapies, which may inform new therapeutic avenues. In this review, we revisit concepts in AR signaling and current understandings of AR signaling-dependent resistance mechanisms as well as the next frontier of AR targeting in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital Cancer Center, Boston, MA.
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
- Dana-Farber Cancer Institute, Boston, MA.
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.
- Department of Urology, University of Minnesota, Minneapolis, MN.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
ORCID-Profile: Charles Dai, Nima Sharifi
Förderung
- NCI NIH HHS
Zitieren
APA
Dai, C., Dehm, S. M., & Sharifi, N. (2023). Targeting the Androgen Signaling Axis in Prostate Cancer. Journal of Clinical Oncology, 41(26), 4267-4278. https://doi.org/10.1200/jco.23.00433
Vancouver
Dai C, Dehm SM, Sharifi N. Targeting the Androgen Signaling Axis in Prostate Cancer. Journal of Clinical Oncology. 2023;41(26):4267-4278. doi:10.1200/jco.23.00433
BibTeX
@article{Dai2023,
author = {Dai, Charles and Dehm, Scott M and Sharifi, Nima},
title = {Targeting the Androgen Signaling Axis in Prostate Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {26},
pages = {4267--4278},
doi = {10.1200/jco.23.00433}
}
EUVIMED